| Literature DB >> 17129816 |
Jagadeshwar G Reddy1, Edward V Loftus.
Abstract
In many ways, infliximab has drastically altered expectations for medical therapy in IBD, and it is expected that adalimumab and certolizumab pegol with ultimately have a similar role. Patients initiating such therapy should be made cognizant of the potential risks of serious infection including opportunistic ones, such as TB and histoplasmosis; demyelinating disorders; CHF; and lymphoma. Proper selection of candidates for anti-TNF-alpha therapy is critical in maintaining a proper benefit-to-risk ratio.Entities:
Mesh：
Substances：
Year: 2006 PMID： 17129816 DOI： 10.1016/j.gtc.2006.09.008
Source DB: PubMed Journal: Gastroenterol Clin North Am ISSN： 0889-8553 Impact factor: 3.806